Latest Posts
Travecta Therapeutics announces it has closed its oversubscribed Series A Round at $27 Million
Travecta Therapeutics, a biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, announces today it has raised an additional $12 million...
Travecta Therapeutics Presents at Ventures Day Singapore in 2020
WE HAD ANOTHER SUCCESSFUL VENTURES DAY IN SINGAPORE. Travecta Therapeutics presented its technology and showcased its achievements at another SPRIM’s Ventures Day in Singapore. Following our three...
Travecta showcases its novel blood-brain barrier transport platform in New York, USA
Travecta Therapeutics is one of eight companies that will present at SPRIM’s quarterly Ventures Day meeting in New York on April 24. The event will provide insights into the latest innovations and...
Travecta Therapeutics presents corporate updates at TKS 1 Investor Day in Singapore
Travecta Therapeutics, an emerging biotech company utilizing its novel Blood-Brain Barrier (BBB) Transport Platform to develop a proprietary pipeline of molecules that treat disorders of the central...
Tackling the blood-brain barrier: Duke-NUS discovery leads to startup Travecta
Travecta Therapeutics Pte Ltd. is the latest startup to join Singapore’s biotech block. The newly formed drug discovery company is based on intellectual property derived from discoveries made at...
Duke-NUS commercializes discovery to deliver therapeutics across blood brain barrier
Intellectual property (IP) derived from discoveries made at Duke-NUS Medical School (Duke-NUS) have been licensed to a newly formed biotech start-up, Travecta Therapeutics Pte Ltd, a Singapore-based...